Effect of etelcalcetide on cardiac hypertrophy in hemodialysis patients: a randomized controlled trial (ETECAR-HD)

Effect of etelcalcetide on cardiac hypertrophy in hemodialysis patients: a randomized controlled trial (ETECAR-HD)

Abstract Background Fibroblast growth factor 23 (FGF23) is associated with left ventricular hypertrophy (LVH) in patients with chronic kidney disease, and calcimimetic therapy reduces plasma concentrations of FGF23. It remains unknown whether treatment with the calcimimetic etelcalcetide (ETL) reduc...

Full description

Bibliographic Details
Main Authors: Katharina Dörr, Michael Kammer, Roman Reindl-Schwaighofer, Matthias Lorenz, Christian Loewe, Rodrig Marculescu, Reinhold Erben, Rainer Oberbauer
Format: Article
Language:English
Published: BMC 2019-10-01
Series:Trials
Subjects:
Hemodialysis
Left ventricular hypertrophy
Secondary hyperparathyroidism
FGF23
Etelcalcetide
Alfacalcidol
Online Access:http://link.springer.com/article/10.1186/s13063-019-3707-7

Internet

http://link.springer.com/article/10.1186/s13063-019-3707-7

Similar Items